Physician profile
Weldon Dee Green
NPI 1609977511
$402.60
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $83.60 · 2021: $47.74 · 2022: $41.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $89.61 | 2019-2020 | |
| Allergan, INC. | $72.12 | 2019-2020 | |
| Pfizer INC. | $59.96 | 2019-2020 | |
| Novo Nordisk INC | $29.52 | 2020 | |
| Abbvie INC. | $29.02 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.67 | 2019 | |
| Glaxosmithkline, LLC. | $23.65 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $23.55 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.00 | 2021 | |
| Lilly USA, LLC | $12.82 | 2019 | |
| Smith+Nephew, INC. | $12.49 | 2022 | |
| Amgen INC. | $11.19 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weldon Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.